Benefits and harms of selective oestrogen receptor modulators (SERMs) to reduce breast cancer risk: a cross-sectional study of methods to communicate risk in primary care.

CONCLUSION: Specific risk formats may lead to more women considering taking SERMs to reduce breast cancer risk, especially if they are at high risk of the condition. Raloxifene may be a more acceptable SERM to patients. PMID: 31636127 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31636127?dopt=Abstract

Source: The British Journal of General Practice - October 20, 2019 Category: Primary Care Authors: McIntosh JG, Minshall J, Saya S, Bickerstaffe A, Hewabandu N, Qama A, Emery JD Tags: Br J Gen Pract Source Type: research